5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IDR, QFIN, SEZL, CORT, FINW.
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?
The mean of analysts' price targets for Corcept (CORT) points to a 43% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept: Key Announcements Coming Soon
Corcept's upcoming Q4 announcements include pivotal trial results for Relacorilant in ovarian cancer, Dazucorilant in ALS, and an NDA filing for Relacorilant in Cushing's. Positive results from these trials could significantly boost CORT's revenue potential, especially in non-Cushing's applications like cancer and ALS. Corcept's academic alliances enhance its research capabilities, supporting the development of diverse cortisol modulators for various diseases.
Here's Why Investors Should Consider Buying Corcept Stock Now
Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Corcept (CORT) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it “is impressive and difficult to ignore.”
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept Shares Rise More Than 45% in Six Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
Corcept (CORT) Upgraded to Buy: Here's Why
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
